Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00298714|
Recruitment Status : Completed
First Posted : March 3, 2006
Last Update Posted : November 22, 2007
There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis.
The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).
|Condition or disease||Intervention/treatment||Phase|
|Chronic Hepatitis C Liver Fibrosis||Drug: Losartan||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis.|
|Study Start Date :||March 2003|
|Actual Study Completion Date :||January 2006|
- Assessment of liver fibrogenesis by changes in gene expression of key mediators of liver fibrosis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00298714
|Principal Investigator:||Pere Ginès, M.D.||Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona|
|Study Chair:||Vicente Arroyo, M.D.||Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona|